SCHEMBL26620439

SCHEMBL26620439

CC(=O)c1cc(N2CCN(C(=O)OCc3ccccc3)CC2)nc(Cl)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPEPLD Q6IQ20 1/20 0.51
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TMEM97 Q5BJF2 9/20 0.45
SIGMAR1 Q99720 9/20 0.45
HRH1 P35367 2/20 0.45
HRH3 Q9Y5N1 2/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
DRD1 P21728 1/20 0.45
HRH2 P25021 1/20 0.45
HTR1B P28222 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23702506 0.91 NAPEPLD (0.50) NAPEPLDMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL23702477 0.89 NAPEPLD (0.53) NAPEPLDMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL18153363 0.87 MEN1 (0.50) NAPEPLDMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL30111555 0.82 HDAC1 (0.51) NAPEPLDMEN1KMT2ANPSR1SIGMAR1
SCHEMBL30796957 0.80 TRPV1 (0.53) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL23702581 0.80 NAPEPLD (0.47) NAPEPLDMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL30111427 0.80 NAPEPLD (0.47) NAPEPLDMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL30111440 0.80 NAPEPLD (0.49) NAPEPLDNPSR1SMN1; SMN2HDAC1MAPT
SCHEMBL13667249 0.79 SMN1; SMN2 (0.56) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL14804592 0.78 NAPEPLD (0.48) NAPEPLDMEN1KMT2ANPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339910-A1 RAS INHIBITORS AND METHODS OF USING THE SAME JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2023-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339910-A1 RAS INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS NAPEPLD 4198/4885MEN1 857/4885KMT2A 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.